AIM ImmunoTech has completed dosing in its Phase 2 DURIPANC trial for Ampligen in metastatic pancreatic cancer and expects topline results in Q1 2027, with survival data by mid-2027. Ampligen, an immune-stimulating drug, is being evaluated for use alongside emerging RAS-targeted therapies to potentially improve treatment outcomes. These upcoming results will guide the design of a pivotal Phase 3 trial, aiming to position Ampligen as a maintenance therapy in the evolving pancreatic cancer treatment landscape. The company also reported a net loss of $3.1 million for Q3 2026 and holds $6.9 million in cash and equivalents.
AIM ImmunoTech's upcoming Phase 2 pancreatic cancer data is a key development to watch. For readers following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 20:42 WIB: Out of 150 priced US health stocks, 107 rose and 39 fell today. Notable movers include WGS (GeneDx Holdings Corp) at USD 48.00 with a -7.46% change, HRTX (Heron Therapeutics Inc) at USD 0.35 up 5.80%, and CTXR (Citius Pharmaceuticals Inc) at USD 0.51 down 4.21%. Typical hold times range from 19 to 39 days, with varied Pluang order activity.
The Beer Institute recognized 16 outstanding professionals with its 2026 BEST IN BREW Honors, celebrating their exceptional contributions across brewing, supply chain, and leadership roles in the U.S. beer industry. This annual award highlights the d...
REalloys Inc. reported a net loss of $30.5 million in Q3 2026 but made significant progress by signing a non-binding term sheet with the U.S. Army for a heavy rare earth processing facility at Tooele Army Depot, Utah. The company is advancing its met...
Modern Mining Technology Corp. began trading on the NYSE American after raising nearly $40 million in an IPO. The company recovers valuable metals like gold, silver, and copper from electronic waste using a proprietary process, avoiding traditional m...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
